文献速递泌尿男性生殖肿瘤

外照射放疗联合近距离放疗与单纯近距离放疗治疗中危前列腺癌的疗效:NRG肿瘤学RTOG 0232随机临床试验

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
PubMed 文献 · J Clin Oncol · 2023-06-14

NRG肿瘤学RTOG 0232随机临床试验纳入588例中危前列腺癌患者,比较外照射放疗联合近距离放疗(COMBO)与单纯近距离放疗。两组5年无进展生存率无显著差异,但COMBO组晚期泌尿生殖系统和胃肠道2级及以上毒性显著更高。结论认为单纯近距离放疗可作为中危前列腺癌的标准治疗选择。

要点

  • COMBO组与单纯近距离放疗组5年FFP-ASTRO分别为85.6%和82.7%,差异无统计学意义(OR 0.80,95%CI 0.51-1.26,P=0.18)。
  • COMBO组晚期GU/GI 2级及以上毒性5年累积发生率42.8%,显著高于单纯近距离放疗组的25.8%(P<0.0001)。
  • 单纯近距离放疗可考虑作为中危前列腺癌的标准治疗。

核心结论

  • 与单纯近距离放疗相比,COMBO未改善中危前列腺癌患者的无进展生存,但导致更严重的毒性。
  • 单纯近距离放疗可考虑作为中危前列腺癌男性的标准治疗。

研究设计与样本

  • 随机临床试验(NRG Oncology RTOG 0232),纳入588例随机分组、579例符合条件的中危前列腺癌患者(COMBO组287例,单纯近距离放疗组292例)。
  • 入组条件为前列腺癌分期cT1c-T2bN0M0,Gleason评分2-6且前列腺特异性抗原10-20 ng/mL,或Gleason评分7且PSA<10 ng/mL。
  • COMBO组方案:外照射放疗45 Gy/25次照射前列腺及精囊,随后近距离放疗前列腺推量(125-I为110 Gy,103-Pd为100 Gy)。
  • 单纯近距离放疗组仅照射前列腺(125-I为145 Gy,103-Pd为125 Gy)。
  • 主要终点为无进展生存(FFP),定义为PSA失败(ASTRO或Phoenix标准)、局部失败、远处失败或死亡。

主要发现

  • 中位年龄67岁;89.1%患者PSA<10 ng/mL,89.1%患者Gleason评分7,66.7%患者T1期。
  • 5年FFP-ASTRO:COMBO组85.6%(95%CI 81.4-89.7)vs 单纯近距离放疗组82.7%(95%CI 78.3-87.1),OR 0.80(95%CI 0.51-1.26),Greenwood T P=0.18。
  • 5年FFP-Phoenix:COMBO组88.0%(95%CI 84.2-91.9)vs 单纯近距离放疗组85.5%(95%CI 81.3-89.6),OR 0.80(95%CI 0.49-1.30),Greenwood T P=0.19。
  • 急性和晚期泌尿生殖系统及胃肠道毒性:两组急性毒性无差异。
  • 5年晚期GU/GI 2级及以上毒性累积发生率:COMBO组42.8%(95%CI 37.0-48.6)vs 单纯近距离放疗组25.8%(95%CI 20.9-31.0),P<0.0001。

临床怎么用

  • 单纯近距离放疗可考虑作为中危前列腺癌的标准治疗。
  • COMBO未改善无进展生存且增加晚期毒性,与单纯近距离放疗相比未显示优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) compared with BT alone would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer. METHODS: Men with prostate cancer stage cT1c-T2bN0M0, Gleason Score (GS) 2-6 and prostate-specific antigen (PSA) 10-20 or GS 7, and PSA < 10 were eligible. The COMBO arm was EBRT (45 Gy in 25 fractions) to prostate and seminal vesicles followed by BT prostate boost (110 Gy if 125-Iodine, 100 Gy if 103-Pd). BT arm was delivered to prostate only (145 Gy if 125-Iodine, 125 Gy if 103-Pd). The primary end point was FFP: PSA failure (American Society for Therapeutic Radiology and Oncology [ASTRO] or Phoenix definitions), local failure, distant failure, or death. RESULTS: Five hundred eighty-eight men were randomly assigned; 579 were eligible: 287 and 292 in COMBO and BT arms, respectively. The median age was 67 years; 89.1% had PSA < 10 ng/mL, 89.1% had GS 7, and 66.7% had T1 disease. There were no differences in FFP. The 5-year FFP-ASTRO was 85.6% (95% CI, 81.4 to 89.7) with COMBO compared with 82.7% (95% CI, 78.3 to 87.1) with BT (odds ratio [OR], 0.80; 95% CI, 0.51 to 1.26; Greenwood T P = .18). The 5-year FFP-Phoenix was 88.0% (95% CI, 84.2 to 91.9) with COMBO compared with 85.5% (95% CI, 81.3 to 89.6) with BT (OR, 0.80; 95% CI, 0.49 to 1.30; Greenwood T P = .19). There were no differences in the rates of genitourinary (GU) or GI acute toxicities. The 5-year cumulative incidence for late GU/GI grade 2+ toxicity is 42.8% (95% CI, 37.0 to 48.6) for COMBO compared with 25.8% (95% CI, 20.9 to 31.0) for BT (P < .0001). The 5-year cumulative incidence for late GU/GI grade 3+ toxicity is 8.2% (95% CI, 5.4 to 11.8) compared with 3.8% (95% CI, 2.0 to 6.5; P = .006). CONCLUSION: Compared with BT, COMBO did not improve FFP for prostate cancer but caused greater toxicity. BT alone can be considered as a standard treatment for men with intermediate-risk prostate cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Michalski JM, Winter KA, Prestidge BR, et al. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. J Clin Oncol. 2023. PMID: 37315297. doi:10.1200/JCO.22.01856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。